Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281419 | 0.92 | PTGS2 (0.85) | PTGS2PTGS1 | |
| SCHEMBL3252361 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL30355967 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5593877 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL215075 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3241987 | 0.86 | PTGS2 (0.85) | PTGS2PTGS1 | |
| SCHEMBL5594093 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7158835 | 0.85 | PTGS2 (0.95) | PTGS2PTGS1 | |
| SCHEMBL5594035 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5071006 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1479385-B1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | SEARLE LLC (US) | 2008-07-02 | — | — | EP | claimed |
| CN-1332661-C | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2007-08-22 | — | — | CN | claimed |
| US-20070072861-A1 | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | RONIKER BARBARA | 2007-03-29 | — | — | US | claimed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | claimed |
| CN-1767835-A | Compositions comprising cyclooxygenase-2 selective inhibitors and glucosamine for the treatment and prevention of pain and inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| CN-1697654-A | Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | UPJOHN CO (US) | 2005-11-16 | — | — | CN | claimed |
| EP-0833622-B8 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-10-12 | — | — | EP | claimed |
| CN-1660083-A | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | G D SIORL & CO (US) | 2005-08-31 | — | — | CN | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997029775-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997029774-A1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997027181-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-07-31 | — | — | WO | claimed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | claimed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072861-A1 | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | PTGS2, PTGES2, PTGIS | PTGS2 1/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.